New medication used for weight reduction might also cut back dangers of coronary heart assaults. A pharmaceutical large desires Medicare to cowl the medication, however a federal ban prevents Medicare from masking weight reduction medication.
STEVE INSKEEP, HOST:
A drug firm has been lobbying Congress to get Medicare to cowl its weight reduction medication. Novo Nordisk makes Wegovy and Ozempic. These are very fashionable medication. And except for weight reduction, the corporate claims they might forestall coronary heart assaults. However many individuals want some huge cash to pay for the medication. Many insurance coverage don’t cowl them, and the corporate is leaning on lawmakers to get it coated below Medicare, the well being care program for seniors. Rachana Pradhan from our associate KFF Well being Information is right here to debate this. Good morning.
RACHANA PRADHAN, BYLINE: Good to be with you, Steve. Thanks.
INSKEEP: Why does not Medicare cowl these medication?
PRADHAN: Effectively, there may be an express ban below federal regulation that claims that Medicare’s prescription drug profit can’t cowl medication which can be used for weight reduction.
INSKEEP: I might like to grasp why there could be a ban, as a result of it does appear apparent for many individuals in lots of well being conditions that dropping some weight can be helpful for them. So why would the federal regulation explicitly forbid that type of drug?
PRADHAN: Effectively, when Medicare’s prescription drug profit was created in 2003, we have been residing in a distinct time. Weight reduction medication that have been available on the market weren’t almost as efficient as the brand new technology of medicine that we’re seeing available on the market now. And at the moment, it was actually contemporary, I feel, in lawmaker’s reminiscence that there have been some fairly main eating regimen tablet debacles that made lawmakers extraordinarily skeptical about masking these medication below Medicare.
INSKEEP: So there was this surroundings 20 years in the past when the regulation was handed. Now issues have modified, or Novo Nordisk would love folks to suppose so anyway. What are they doing to attempt to get Congress to vary this ban in order that Medicare would cowl their medication?
PRADHAN: They’re targeted on the Congressional Black Caucus and associations which can be type of affiliated with that caucus of lawmakers to speak their message and get allies of their pursuit of this coverage purpose.
INSKEEP: Does this embrace marketing campaign contributions or what?
PRADHAN: Effectively, definitely Novo Nordisk and different pharmaceutical firms give marketing campaign money to lawmakers no matter political celebration. However they oftentimes will sponsor panels, webinars and provides to those nonprofits which can be related to these totally different teams of lawmakers as a strategy to type of bolster their advocacy work, if you’ll.
INSKEEP: Is that this notably dangerous, although? I am desirous about research that discover that Black Individuals do have sure sorts of well being issues extra typically than different folks, and that may embrace issues like coronary heart assaults and strokes and weight problems.
PRADHAN: For certain. I imply, based mostly on physique mass index, the BMI, African Individuals have the best charges of weight problems within the U.S. And so I feel there is a purpose why Novo Nordisk would need Black figures to be part of its messaging on this. And it’s true that these medication actually do have vital profit in that the load loss expertise amongst sufferers could be very vital. Nonetheless, as with something in American medication, you possibly can’t separate prices from the advantages. And any drug, no matter what it’s, has advantages but in addition has dangers. And so I feel that that’s the factor that must be balanced – proper? – which is that it’s important to take a look at the larger image from all of those various factors.
INSKEEP: Rachana Pradhan of KFF Well being Information has been masking a lobbying effort by Novo Nordisk for its weight reduction medication. Thanks a lot.
PRADHAN: Thanks.
Copyright © 2023 NPR. All rights reserved. Go to our web site phrases of use and permissions pages at www.npr.org for additional info.
NPR transcripts are created on a rush deadline by an NPR contractor. This textual content will not be in its remaining kind and could also be up to date or revised sooner or later. Accuracy and availability might differ. The authoritative report of NPR’s programming is the audio report.
